Neurology
Alzheimer's Disease
21
Pipeline Programs↗
94
Active Trials↗
73
Companies Involved↗
Alzheimer's Disease is an emerging landscape with 21 programs across 73 companies. The most active players are ChainGen Biopharma Ltd, Alnylam Pharmaceuticals, Daiichi Sankyo. 3 therapies are approved with 7 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 16
Phase 21
Analysis
Modality Breakdown
17programs
Small molecule953%
Monoclonal antibody424%
Radiopharmaceutical212%
RNA therapy16%
Gene therapy16%
Modality classified for 68% of 28 pipeline programs.
Analysis
Trial Status
535
clinical trials
Completed321 · 60%
Terminated61 · 11%
Recruiting52 · 10%
Unknown status46 · 9%
Not yet recruiting25 · 5%
Active, not recruiting13 · 2%
Other17 · 3%
Clinical Trials
Trial Activity
535 trials
Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease
Recruiting·—·N/A·NCT03810794·180 enrolled
Page 1 of 36
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)